JUNEVITY

Live / Applied — Second extension granted (statement of use) (as of 08 Jan 2026)

What this means for you

Not registered yet, but its 04 Aug 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
98117779
Mark type
Stylized text
Filed
04 Aug 2023
Published for opposition
03 Dec 2024
Attorney of record
Christina M. Licursi

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of human diseases and disorders, namely, metabolic disease, liver diseases, diabetes, obesity, muscle wasting and frailty, dementia and neurological diseases, skin diseases, chronic kidney disease, inflammatory diseases, and lung diseases; pharmaceutical preparations for the treatment of physiological diseases; pharmaceutical products for cell therapy to treat human diseases and disorders, as well as aging; cell therapy products, namely, pharmaceutical preparations for cell therapy to treat human aging, diseases, and disorders, namely, metabolic disease, liver diseases, diabetes, obesity, muscle wasting and frailty, dementia and neurological diseases, skin diseases, chronic kidney disease, inflammatory diseases, and lung diseases; pharmaceutical preparations for gene therapy to treat human diseases and disorders; pharmaceutical gene therapy preparations to treat human diseases and disorders; chemical preparations for pharmaceutical or medical purposes, namely, for gene and cell therapy
  • Class 042 — Scientific and technological services: Research and development in the field of pharmaceutical development; medical and scientific research and development in connection with cell aging and restoration; research and development of new products in the pharmaceutical and biotechnology fields; development of new technology for others in the fields of gene therapy, genome writing, and genome engineering; scientific research and development in the field of pharmaceutical preparations for gene therapy; scientific research and development in the field of enzyme preparations for gene and cell therapy; research and development services in the field of genomics; medical and scientific research in the fields of genomics; providing medical and scientific research information in the fields of genomics; medical and scientific research in the field of genetics for the purpose of elevating single cell genome variants in order to identify transcription factors; scientific research and development and scientific research consulting, all in the field of genomics; medical research, namely, compiling data for research purposes in the field of genomics; providing medical research information in the field of genomics in relation to disease treatment and aging; providing on-line non-downloadable software for collecting, analyzing, reporting, and tracking data and information in the field of genomics; platform as a service (PAAS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the field of genomics; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the field of genomics; providing temporary use of non-downloadable computer software incorporating machine learning (ML) and artificial intelligence (AI) technology for genomic analysis and sequencing for scientific, medical, and research purposes; providing temporary use of non-downloadable computer software incorporating machine learning (ML) and artificial intelligence (AI) technology for medical and scientific research in the field of genomics; providing temporary use of non-downloadable computer software for providing medical and scientific research information in the field of genomics; providing temporary use of non-downloadable computer software for medical and scientific research in connection with detecting variants in cells to treat disease and mitigate aging; providing temporary use of non-downloadable computer software for research, development and consultancy in the field of genomics; providing temporary use of non-downloadable computer software for compiling data for research purposes in the field of genomics; providing temporary use of non-downloadable computer software for providing medical research information in the field of genomics; providing temporary use of non-downloadable computer software for medical testing, diagnosis, and treatment; providing temporary use of non-downloadable computer software for medical analysis and diagnosis in the field of genomics for the purpose of disease treatment; providing temporary use of non-downloadable computer software for medical analysis and diagnosis in the field of genomics; providing temporary use of non-downloadable computer software for medical and scientific research in connection with aging

Owner

Prosecution history

  • 09 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 08 Jan 2026 — SOU EXTENSION 2 GRANTED
  • 08 Jan 2026 — SOU EXTENSION 2 FILED
  • 08 Jan 2026 — SOU TEAS EXTENSION RECEIVED
  • 22 Sept 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 22 Sept 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
  • 22 Sept 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
  • 22 Sept 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 22 Sept 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
  • 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 27 May 2025 — SOU EXTENSION 1 GRANTED
  • 27 May 2025 — SOU EXTENSION 1 FILED
  • 27 May 2025 — SOU TEAS EXTENSION RECEIVED
  • 14 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 03 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

View this trademark record on Marksy